Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065609 · ClinicalTrials.gov registry record · Early Phase 1
89ZrTrastuzumab Breast Imaging With Positron Emission Tomography
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
NCT02065609 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 52 participants.
The verdict
NCT02065609, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
Interventions
- DRUG 89Zr-Trastuzumab Human Dosimetry and Safety
- DRUG HER2 Positive Lesion Detection and Safety
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-02-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065609
The ClinicalTrials.gov registry entry for NCT02065609 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 89Zr-Trastuzumab Human Dosimetry and Safety is the first listed.
NCT02065609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02065609 about?
NCT02065609 is a clinical study titled "89ZrTrastuzumab Breast Imaging With Positron Emission Tomography". The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
What is the current status of trial NCT02065609?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2014-02. Estimated completion is 2018-02-13.
What interventions are being tested in trial NCT02065609?
The interventions under investigation include: 89Zr-Trastuzumab Human Dosimetry and Safety (DRUG), HER2 Positive Lesion Detection and Safety (DRUG).
Who is sponsoring clinical trial NCT02065609?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.